Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESPINE: Allogeneic BM-MSCs for Lumbar DDD
NCT03737461Phase 3Active, not recruiting
- Sponsor
- CHU Montpellier
- Start
- Feb 2019
- Primary completion
- May 2022
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in degenerative disc disease (DDD) and chronic low back pain (CLBP) (2 arms), sponsored by CHU Montpellier. Primary endpoints: Change from Baseline Pain Clinical response at 12 months and Change from Baseline Oswestry Disability Index (ODI) measure at 12 months. Started Feb 2019; status: active, not recruiting.
02
Conditions
degenerative disc disease (DDD)chronic low back pain (CLBP)
Beyond the preview
Go deeper on NCT03737461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03737461.